146 related articles for article (PubMed ID: 33176663)
1. The Anti-Proliferative Effect of a Newly-Produced Anti-PSCA-Peptide Antibody by Multiple Bioinformatics Tools, on Prostate Cancer Cells.
Chizari M; Fani-Kheshti S; Taeb J; Farajollahi MM; Mohsenzadegan M
Recent Pat Anticancer Drug Discov; 2021; 16(1):73-83. PubMed ID: 33176663
[TBL] [Abstract][Full Text] [Related]
2. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
3. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M
Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097
[TBL] [Abstract][Full Text] [Related]
4. MRl of prostate cancer antigen expression for diagnosis and immunotherapy.
Ren J; Wang F; Wei G; Yang Y; Liu Y; Wei M; Huan Y; Larson AC; Zhang Z
PLoS One; 2012; 7(6):e38350. PubMed ID: 22761679
[TBL] [Abstract][Full Text] [Related]
5. Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer.
Kessler C; Pardo A; Tur MK; Gattenlöhner S; Fischer R; Kolberg K; Barth S
J Cancer Res Clin Oncol; 2017 Oct; 143(10):2025-2038. PubMed ID: 28667390
[TBL] [Abstract][Full Text] [Related]
6. Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer.
Matsueda S; Kobayashi K; Nonaka Y; Noguchi M; Itoh K; Harada M
Cancer Immunol Immunother; 2004 Jun; 53(6):479-89. PubMed ID: 14634796
[TBL] [Abstract][Full Text] [Related]
7. Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells.
Arndt C; Feldmann A; Töpfer K; Koristka S; Cartellieri M; Temme A; Ehninger A; Ehninger G; Bachmann M
Prostate; 2014 Sep; 74(13):1347-58. PubMed ID: 25053504
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system.
Arndt C; Feldmann A; Koristka S; Cartellieri M; Dimmel M; Ehninger A; Ehninger G; Bachmann M
Prostate; 2014 Sep; 74(13):1335-46. PubMed ID: 25053443
[TBL] [Abstract][Full Text] [Related]
9. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.
Hillerdal V; Ramachandran M; Leja J; Essand M
BMC Cancer; 2014 Jan; 14():30. PubMed ID: 24438073
[TBL] [Abstract][Full Text] [Related]
10. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer.
Gu Z; Thomas G; Yamashiro J; Shintaku IP; Dorey F; Raitano A; Witte ON; Said JW; Loda M; Reiter RE
Oncogene; 2000 Mar; 19(10):1288-96. PubMed ID: 10713670
[TBL] [Abstract][Full Text] [Related]
11. Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients.
Kiessling A; Schmitz M; Stevanovic S; Weigle B; Hölig K; Füssel M; Füssel S; Meye A; Wirth MP; Rieber EP
Int J Cancer; 2002 Dec; 102(4):390-7. PubMed ID: 12402309
[TBL] [Abstract][Full Text] [Related]
12. Construction of a fusion plasmid containing the PSCA gene and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and its anti-tumor effect in an animal model of prostate cancer.
Mai TJ; Ma R; Li Z; Bi SC
Braz J Med Biol Res; 2016 Oct; 49(11):e5620. PubMed ID: 27783810
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic efficacy of I131-PSCA-mAb in orthotopic mouse models of prostate cancer.
Yu S; Feng F; Wang K; Men C; Lin C; Liu Q; Yang D; Gao Z
Eur J Med Res; 2013 Dec; 18(1):56. PubMed ID: 24330823
[TBL] [Abstract][Full Text] [Related]
14. Small interference RNA-mediated silencing of prostate stem cell antigen attenuates growth, reduces migration and invasion of human prostate cancer PC-3M cells.
Zhao Z; Ma W; Zeng G; Qi D; Ou L; Liang Y
Urol Oncol; 2013 Apr; 31(3):343-51. PubMed ID: 21429770
[TBL] [Abstract][Full Text] [Related]
15. Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer.
Wente MN; Jain A; Kono E; Berberat PO; Giese T; Reber HA; Friess H; Büchler MW; Reiter RE; Hines OJ
Pancreas; 2005 Aug; 31(2):119-25. PubMed ID: 16024997
[TBL] [Abstract][Full Text] [Related]
16. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model.
Simons BW; Cannella F; Rowley DT; Viscidi RP
Cancer Immunol Immunother; 2020 Apr; 69(4):641-651. PubMed ID: 32016503
[TBL] [Abstract][Full Text] [Related]
17. An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors.
Lepin EJ; Leyton JV; Zhou Y; Olafsen T; Salazar FB; McCabe KE; Hahm S; Marks JD; Reiter RE; Wu AM
Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1529-38. PubMed ID: 20354850
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice.
Xiao L; Joo KI; Lim M; Wang P
PLoS One; 2012; 7(11):e48866. PubMed ID: 23139820
[TBL] [Abstract][Full Text] [Related]
19. [Expression of prostate stem cell antigen (PSCA) and selection of its specific binding peptide].
Hou LH; Du Y; Zhang XP; An XP; Chen W
Sheng Wu Gong Cheng Xue Bao; 2004 Sep; 20(5):694-8. PubMed ID: 15973992
[TBL] [Abstract][Full Text] [Related]
20. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer.
Reiter RE; Gu Z; Watabe T; Thomas G; Szigeti K; Davis E; Wahl M; Nisitani S; Yamashiro J; Le Beau MM; Loda M; Witte ON
Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1735-40. PubMed ID: 9465086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
